IntoCell

IntoCell EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of IntoCell (287840.KQ) as of Oct 31, 2026 is -76.81. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -80.81 — a change of -4.95% (higher).

EV/EBIT

-76.81

YoY

-4.95%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of IntoCell is 2025 -76.81 . EV/EBIT (Enterprise Value to EBIT) of IntoCell was 2024 -80.81 . It decreases by -4.95% higher compared to the previous year.

The IntoCell EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2022
-83.62 KRW
Jan 1, 2023
-45.49 KRW
Jan 1, 2024
-80.81 KRW
Jan 1, 2025
-76.81 KRW
Jan 1, 2026 (e)
-49.94 KRW
The IntoCell EV/EBIT history
YEAREV/EBITYoY
est-49.94-34.98%
-76.81-4.95%
-80.81+77.62%
-45.49-45.59%
-83.62—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IntoCell Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides IntoCell's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates IntoCell's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots IntoCell's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if IntoCell grows earnings faster than its peers.

IntoCell Stock analysis

What does IntoCell do? IntoCell, Inc. generates revenue through the development and licensing of its ADC platform technologies, including the OHPAS linker technology and PMT platform technology. The company focuses on creating proprietary drug technologies for ADC development, targeting pharmaceutical companies seeking to improve drug delivery systems. Its primary customers are pharmaceutical firms interested in enhancing the efficacy and safety of antibody-drug conjugates through advanced linker and payload modification solutions. The OHPAS platform technology serves as a critical linker connecting drugs to antibodies, while the PMT platform technology reduces drug uptake into normal cells, addressing key challenges in ADC development. IntoCell's proprietary drug technology complements these platforms, offering specialized solutions for ADC manufacturers. The company's R&D-driven approach positions it as a provider of innovative tools for the biopharmaceutical industry. IntoCell's business model centers on technology licensing and development contracts with pharmaceutical partners. By leveraging its expertise in linker and payload modification, the company aims to secure long-term partnerships that drive revenue through milestone payments and royalties on commercialized products. The firm's focus on proprietary technologies ensures a competitive edge in the ADC market. IntoCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IntoCell stock

EV/EBIT (Enterprise Value to EBIT) of IntoCell is -76.81 in 2025.

EV/EBIT (Enterprise Value to EBIT) of IntoCell changed from -80.81 to -76.81, representing a -4.95% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) IntoCell since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s IntoCell with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — IntoCell

All Key Metrics — IntoCell